TORONTO, July 12, 2018 /CNW/ - GeneNews Limited
("GeneNews" or the "Company") (TSX:GEN) today announced the
appointment of David Byram as the
Chief Commercial Officer for its U.S. Lab, Innovative Diagnostic
Laboratory, LLP ("IDL"). Mr. Byram will oversee all IDL's
customer-facing activities including sales, client relations and
commercial operations.
Mr. Byram is a senior commercial executive with over 25 years of
pharmaceutical, biotechnology and medical device industry
leadership experience. He has built successful product launches
across multiple therapeutic areas that incorporate innovative sales
and marketing strategies which have driven wide market adoption and
revenue generation. Mr. Byram has broad health category experience
including oncology/hematology, gastroenterology, rheumatology,
neurology, cardiology and urology. During his career, Mr.
Byram has overseen all commercial operations including sales and
marketing, market access and pricing, channel strategy and new
product development. Prior to joining IDL, Mr. Byram was the
Vice President, Commercial & Government Affairs for Braeburn
Pharmaceuticals. Prior to Braeburn, he held positions as SVP,
Commercial Affairs for Orexo AB/US, US Director, Public Sector for
Indivior plc, and Sr. Director, Strategic Accounts and Public
Affairs for Janssen Biotech, a division of Johnson & Johnson.
David is highly focused on delivering healthcare outcomes which
create value for patients, physicians, payers and
investors.
"We are extremely pleased to have David join IDL's senior
leadership team," commented James R Howard-Tripp, Chairman and CEO
of GeneNews. "With a very experienced executive to energetically
manage the company's commercial operations and sales strategy, we
can increase the pace of meeting our targeted sales objectives for
2018."
"It is an exciting time to be in the liquid biopsy space and I
look forward to utilizing my commercialization expertise as well as
prior sales experience in oncology and gastroenterology to support
IDL's efforts to achieve our growth objectives and ensure the
highest satisfaction of our clients," said Mr. Byram.
About GeneNews
GeneNews, an innovator in the liquid biopsy space, is committed
to becoming a leader in advanced diagnostics and personalized
medicine, serving as a strong commercialization outlet for early
detection of cancer and other chronic diseases. Our mission is to
identify, assess and make commercially available a comprehensive
menu of diagnostics that provide physicians and patients with
personalized clinical intelligence and actionable information to
improve health outcomes through the early diagnosis of disease.
Our Richmond, Virginia-based
Innovative Diagnostic Laboratory clinical reference lab specializes
in traditional and advanced clinical evidence-based blood testing
that helps find, understand, and address cancer risk in patient
populations. Currently, IDL offers risk assessment blood tests for
four prevalent cancer types - colon, lung, prostate and breast.
GeneNews' common shares trade on the Toronto Stock Exchange under
the symbol 'GEN'. More information on GeneNews and IDL can be
found at www.GeneNews.com and www.myinnovativelab.com,
respectively.
Forward-Looking Statements
This press release contains forward-looking statements
identified by words such as "expects", "will", "may" and similar
expressions, which reflect the Company's current expectations
regarding future events, including with respect to the receipt of
shareholder approval. The forward-looking statements involve
risks and uncertainties that could cause actual events to differ
materially from those projected herein including the state of the
equity capital markets, the receipt of required approvals, the
future financial and operating performance of the Company and its
subsidiaries, requirements for and availability of additional
capital and the general business and political environment
including in the healthcare sector. Investors should consult the
Company's ongoing quarterly filings and annual reports for
additional information on risks and uncertainties relating to these
forward-looking statements. The reader is cautioned not to rely on
these forward-looking statements. The Company disclaims any
obligation to update these forward-looking statements, except as
required by law.
View original
content:http://www.prnewswire.com/news-releases/genenews-innovative-diagnostic-laboratory-appoints-david-byram-chief-commercial-officer-300679811.html
SOURCE GeneNews Limited